title: To B-(RAF) or not to be.
abstract: The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: reinhard.dummer@usz.ch.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Simone M
authors.initials: SM
authors.lastname: Goldinger
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Widmer
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Jil
authors.initials: J
authors.lastname: Dreier
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Mitchell P
authors.initials: MP
authors.lastname: Levesque
mesh_terms: D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
references.citation: N Engl J Med. 2012 Jul 12;367(2):107-14
references.pmid: 22663011
references.citation: J Invest Dermatol. 2013 Oct;133(10):2436-2443
references.pmid: 23474946
references.citation: Cancer Res. 2008 Feb 1;68(3):650-6
references.pmid: 18245463
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Curr Opin Oncol. 2012 Mar;24(2):150-4
references.pmid: 22316627
references.citation: Nat Genet. 2007 Mar;39(3):347-51
references.pmid: 17293865
references.citation: Cancer Res. 2011 Apr 15;71(8):3098-109
references.pmid: 21393506
references.citation: J Clin Oncol. 2013 May 10;31(14):1767-74
references.pmid: 23569304
references.citation: Nature. 2013 Feb 21;494(7437):361-5
references.pmid: 23376950
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):555-67
references.pmid: 22048237
references.citation: Nature. 2012 Oct 18;490(7420):412-6
references.pmid: 23051752
references.citation: Lancet Oncol. 2013 Jul;14(8):733-40
references.pmid: 23735514
references.citation: Nat Rev Cancer. 2013 May;13(5):365-76
references.pmid: 23535846
references.citation: J Invest Dermatol. 2014 May;134(5):1468-1470
references.pmid: 24025553
references.citation: Lancet Oncol. 2013 Mar;14(3):249-56
references.pmid: 23414587